NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free PROK Stock Alerts $1.64 +0.07 (+4.46%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.54▼$1.6550-Day Range$1.20▼$1.7752-Week Range$1.12▼$13.51Volume466,004 shsAverage Volume547,080 shsMarket Capitalization$386.11 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProKidney alerts: Email Address ProKidney MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside479.3% Upside$9.50 Price TargetShort InterestBearish29.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.65) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.89 out of 5 starsMedical Sector841st out of 938 stocksBiotechnology Industry38th out of 47 stocks 3.2 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, ProKidney has a forecasted upside of 479.3% from its current price of $1.64.Amount of Analyst CoverageProKidney has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.98% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 24.6, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 2.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 2.2 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProKidney this week, compared to 1 article on an average week.MarketBeat Follows5 people have added ProKidney to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have not sold or bought any company stock.Percentage Held by Insiders44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($0.65) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About ProKidney Stock (NASDAQ:PROK)ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesMarch 26, 2024 | bizjournals.comDuring manufacturing pause, ProKidney increases R&D spending to $106.7MMarch 25, 2024 | globenewswire.comProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical OperationsMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProKidney Amidst Strategic Clinical Advancements and Solid Financial OutlookMarch 21, 2024 | globenewswire.comProKidney Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 7, 2024 | realmoney.thestreet.comProKidney assumed with an Equal Weight at Morgan StanleyFebruary 29, 2024 | globenewswire.comProKidney to Participate in Jefferies Biotech on the Bay SummitFebruary 17, 2024 | finance.yahoo.comPROK Mar 2024 7.500 callMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!February 16, 2024 | bizjournals.comNorth Carolina biotech tops $400M in funding for asthma treatmentFebruary 9, 2024 | fool.comProKidney (NASDAQ: PROK)January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on ProKidney (PROK)December 28, 2023 | bizjournals.comStories to Watch in 2024: Leadership changes, manufacturing pause make 2024 critical year for ProKidneyDecember 16, 2023 | ca.finance.yahoo.comPROK Jan 2024 10.000 callDecember 13, 2023 | finance.yahoo.comHere's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock NowNovember 30, 2023 | bizjournals.comProKidney makes two changes to C-suite, terminating long-serving COO and promoting from within for chief business officerNovember 30, 2023 | finance.yahoo.comProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business OfficerNovember 21, 2023 | msn.comProKidney former 10% owner Chamath Palihapitiya discloses sale of over 7M sharesNovember 21, 2023 | finance.yahoo.comProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx ConferenceNovember 17, 2023 | finance.yahoo.comProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call TranscriptNovember 17, 2023 | finance.yahoo.comCompanies Like ProKidney (NASDAQ:PROK) Are In A Position To Invest In GrowthNovember 16, 2023 | finance.yahoo.comAfter Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)November 16, 2023 | markets.businessinsider.comProKidney’s Future Promising: REACT Trial Success and Strategic Enrollment Shift Boosts Buy RatingNovember 15, 2023 | msn.comProKidney pauses manufacturing after audit, company saysNovember 14, 2023 | msn.comProKidney GAAP EPS of -$0.18November 14, 2023 | finance.yahoo.comProKidney Reports Third Quarter Financial ResultsNovember 14, 2023 | finance.yahoo.comProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease TrialsSee More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$16.00 Low Stock Price Target$3.00 Potential Upside/Downside+479.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,470,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-7.66% Debt Debt-to-Equity RatioN/A Current Ratio14.94 Quick Ratio19.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($42.77) per share Price / Book-0.04Miscellaneous Outstanding Shares235,430,000Free Float129,513,000Market Cap$386.11 million OptionableOptionable Beta1.06 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Timothy A. Bertram D.V.M. (Age 69)Ph.D., Founder Comp: $970.4kMr. Todd C. Girolamo Esq. (Age 59)J.D., M.B.A., Chief Legal Officer & Corporate Secretary Comp: $600.17kDr. Bruce Culleton M.D.CEO & DirectorDr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., Senior Vice President of Investor RelationsMs. Mary Weger (Age 65)Chief People Officer Dr. Joseph M. Stavas M.D.M.P.H., Senior VP and Head of Global Clinical Development & Interventional ProceduresDr. Darin J. Weber Ph.D. (Age 56)Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access Mr. Nikhil L. Pereira-KamathChief Business OfficerMr. Richard WilliamsSenior Vice President of Information TechnologyDr. Aparna Sahoo M.D.VP & Head of Global Clinical DevelopmentMore ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODTenaya TherapeuticsNASDAQ:TNYATScan TherapeuticsNASDAQ:TCRXHumacyteNASDAQ:HUMALexeo TherapeuticsNASDAQ:LXEOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 392,815 shares on 3/11/2024Ownership: 1.231%Goldman Sachs Group Inc.Sold 12,602 shares on 3/1/2024Ownership: 0.016%Nuveen Asset Management LLCSold 17,330 shares on 2/15/2024Ownership: 0.058%Barclays PLCBought 48,234 shares on 2/15/2024Ownership: 0.026%Citadel Advisors LLCBought 4,000 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PROK Stock Analysis - Frequently Asked Questions Should I buy or sell ProKidney stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares. View PROK analyst ratings or view top-rated stocks. What is ProKidney's stock price target for 2024? 3 Wall Street analysts have issued 12 month price objectives for ProKidney's shares. Their PROK share price targets range from $3.00 to $16.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 479.3% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts. How have PROK shares performed in 2024? ProKidney's stock was trading at $1.78 at the beginning of the year. Since then, PROK shares have decreased by 7.9% and is now trading at $1.64. View the best growth stocks for 2024 here. When is ProKidney's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PROK earnings forecast. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) posted its earnings results on Tuesday, November, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02. What ETF holds ProKidney's stock? ALPS Medical Breakthroughs ETF holds 177,981 shares of PROK stock, representing 1.93% of its portfolio. Who are ProKidney's major shareholders? ProKidney's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.23%), Vanguard Group Inc. (1.23%), Charles Schwab Investment Management Inc. (0.11%), Nuveen Asset Management LLC (0.06%), Federated Hermes Inc. (0.05%) and Barclays PLC (0.03%). View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROK) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.